James Welker, DO
Internal Medicine · Annapolis, MDNPI 1568423440
Payments from drug & device makers
Across 724 payments — averaging $1136.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$367K
- Novo Nordisk AS$92K
- CSL Behring$77K
- Pfizer$59K
- American Regent$43K
- Portola Pharmaceuticals, LLC$36K
- plus $148K from 20 others
Across 4 payments — averaging $1150.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Actelion Pharmaceuticals, Ltd$4K
- Novo Nordisk AS$350
What the payments were for
- Consulting fees$3,96833%
- Travel & lodging$5,21743%
- Food & beverage$2,99525%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $367,335 |
| Novo Nordisk AS | 456 | $92,444 |
| CSL Behring | 55 | $76,619 |
| Pfizer | 34 | $59,384 |
| American Regent | 19 | $42,810 |
| Portola Pharmaceuticals, LLC | 40 | $35,762 |
| Novartis | 20 | $28,846 |
| AstraZeneca(2 entities) | 5 | $25,527 |
| Roche Products Limited | 11 | $22,208 |
| Boehringer Ingelheim International GmbH | 47 | $18,582 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $13,575 |
| Sanofi US Services Inc. | 4 | $12,845 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $10,674 |
| Shionogi Inc | 3 | $6,972 |
| Boehringer Ingelheim | 1 | $4,895 |
| Boston Scientific | 8 | $2,508 |
| GSK | 1 | $1,638 |
| Shire North American Group Inc | 2 | $33 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Acadia Pharmaceuticals Inc | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $16 |
| Tandem Diabetes Care, Inc. | 1 | $16 |
| Gilead | 1 | $14 |
| Janssen Research & Development, LLC | 2 | $12 |
| Novo Nordisk | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$822,788 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 17 | $12,819 |
| EntrestoSacubitril/Valsartan | 12 | $7,337 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $394 |
| Colchicine | 11 | $298 |
| Ezetimibe | 23 | $226 |
| Spironolactone | 28 | $211 |
| Losartan Potassium | 32 | $199 |
| Atorvastatin Calcium | 33 | $189 |
| ClopidogrelClopidogrel Bisulfate | 27 | $182 |
| Metoprolol Succinate | 23 | $138 |
| Pantoprazole Sodium | 15 | $103 |
| Furosemide | 31 | $93 |
| Amlodipine Besylate | 11 | $81 |
| Tamsulosin Hcl | 12 | $64 |
| Metoprolol Tartrate | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $59,384 | $12,81917 claims |
| NovartisEntresto | $28,846 | $7,33712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Annapolis
- Titus AbrahamAnnapolis$1.7M
- Brian HarveyAnnapolis$220K
- Shishir KhetanRockville$52.1M
- Steven GellerElkridge$15.1M
- Mary HowellHagerstown$6.2M
- Kristen MarroneBaltimore$5.6M
- Jonathan CohenRockville$5M
- Andrea ApoloBethesda$4.8M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Rahul PatelRockville$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.